We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

66 hedge funds and large institutions have $44.3M invested in Cascadian Therapeutics, Inc. in 2013 Q2 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

707% more call options, than puts

Call options by funds: $3.3M | Put options by funds: $409K

Holders
66
Holders Change
+66
Holders Change %
–
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
66
Increased
–
Reduced
–
Closed
–
Calls
$3.3M
Puts
$409K
Net Calls
+$2.89M
Net Calls Change
+$2.89M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$12.6M +$17.3M +1,348,880 New
Millennium Management
2
Millennium Management
New York
$3.31M +$4.52M +351,699 New
JP Morgan Chase
3
JP Morgan Chase
New York
$3.22M +$4.39M +342,005 New
First Manhattan
4
First Manhattan
New York
$3.06M +$4.13M +321,283 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$2.41M +$3.31M +257,709 New
State of Wisconsin Investment Board
6
State of Wisconsin Investment Board
Wisconsin
$2.11M +$2.89M +225,000 New
First Eagle Investment Management
7
First Eagle Investment Management
New York
$2.02M +$2.77M +215,917 New
BIT
8
BlackRock Institutional Trust
California
$1.97M +$2.69M +209,400 New
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$1.49M +$2.03M +158,333 New
Deutsche Bank
10
Deutsche Bank
Germany
$1.27M +$1.73M +134,774 New
BFA
11
BlackRock Fund Advisors
California
$1.03M +$1.4M +109,313 New
Northern Trust
12
Northern Trust
Illinois
$874K +$1.19M +92,876 New
PCM
13
Perkins Capital Management
Minnesota
$851K +$1.16M +90,350 New
Renaissance Technologies
14
Renaissance Technologies
New York
$779K +$1.06M +82,683 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$687K +$943K +73,421 New
D.E. Shaw & Co
16
D.E. Shaw & Co
New York
$630K +$865K +67,380 New
Morgan Stanley
17
Morgan Stanley
New York
$569K +$778K +60,539 New
Citadel Advisors
18
Citadel Advisors
Florida
$477K +$655K +50,961 New
TC
19
TFS Capital
Pennsylvania
$413K +$564K +43,879 New
Goldman Sachs
20
Goldman Sachs
New York
$410K +$559K +43,524 New
PP
21
Paloma Partners
Connecticut
$384K +$527K +41,037 New
BCM
22
Bridgeway Capital Management
Texas
$358K +$488K +37,998 New
Geode Capital Management
23
Geode Capital Management
Massachusetts
$329K +$451K +35,136 New
Allianz Asset Management
24
Allianz Asset Management
Germany
$314K +$429K +33,383 New
LMF
25
LMR Master Fund
Cayman Islands
$290K +$398K +30,992 New
1
2 3

CASC Hedge Fund Activity: Q2 2013 in Review

66 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q2 2013, worth a combined $44.3M.

Buyers outnumbered sellers: 66 funds opened new CASC positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.

  • 66 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $44.3M of Cascadian Therapeutics, Inc. stock for Q2 2013.
  • 66 funds opened new Cascadian Therapeutics, Inc. positions in Q2 2013 and 0 closed out, a net change of +66 holders.

Based on aggregated 13F filings for Q2 2013.